Arcturus Therapeutics (ARCT) Stock Price, News & Analysis

Company Overview

Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on developing medicines based on messenger RNA (mRNA) and other RNA technologies. Headquartered in San Diego, California, the company uses its proprietary LUNAR lipid-mediated delivery platform and STX self-amplifying mRNA technology to design and deliver RNA-based therapeutics and vaccines.

The company’s research and development activities address rare diseases, infectious diseases, respiratory conditions and other areas of significant unmet medical need. Its pipeline has included mRNA-based treatments for metabolic and genetic disorders, including ornithine transcarbamylase deficiency, as well as programs designed to address cystic fibrosis and other conditions. Arcturus has also developed RNA-based vaccine candidates, including a self-amplifying mRNA COVID-19 vaccine developed in collaboration with CSL.

Arcturus was founded in 2013 and has entered into collaborations and licensing arrangements with pharmaceutical companies and other organizations to advance its technologies. The company is led by Joseph E. Payne, who serves as president and chief executive officer. Its activities are primarily focused on research, clinical development and strategic partnerships supporting the development of RNA medicines for patients worldwide.

Key Stats

• Today's Range: $10.25 to $11.58
• 50-Day Range: $7.05 to $16.93
• 52-Week Range: $5.50 to $24.17
• Volume: 831,609 shs
• Average Volume: 625,947 shs
• Market Capitalization: $293.89 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.00
• Consensus Rating: Moderate Buy

Arcturus Therapeutics Stock Analysis - MarketRank™

Arcturus Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 411th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Arcturus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 7 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Arcturus Therapeutics has a consensus price target of $22.00, representing about 111.9% upside from its current price of $10.38.

Amount of Analyst Coverage

Arcturus Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Arcturus Therapeutics are expected to decrease in the coming year, from ($3.48) to ($3.59) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Arcturus Therapeutics is -3.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arcturus Therapeutics is -3.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Arcturus Therapeutics has a P/B Ratio of 1.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

23.02% of the float of Arcturus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Arcturus Therapeutics has a short interest ratio ("days to cover") of 5.93.

Change versus previous month

Short interest in Arcturus Therapeutics has recently decreased by 1.64%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: Weak

Dividend Yield

Arcturus Therapeutics does not currently pay a dividend.

Dividend Growth

Arcturus Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 1.23

News Sentiment

Arcturus Therapeutics has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Arcturus Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 6 people have searched for ARCT on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

MarketBeat Follows

2 people have added Arcturus Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Arcturus Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.80% of the stock of Arcturus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

94.54% of the stock of Arcturus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 10/16/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ARCT
• CIK: 1768224
• Web: www.arcturusrx.com
• Phone: (858) 900-2660
• Fax: N/A
• Employees: 111
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Arcturus Therapeutics: $22.00
• High Price Target: $41.00
• Low Price Target: $9.00
• Potential Upside/Downside: +112.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$65.78 million
• Net Margins: -317.62%
• Pretax Margin: -317.64%
• Return on Equity: -46.54%
• Return on Assets: -36.46%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.88
• Quick Ratio: 5.88

Sales & Book Value

• Annual Sales: $18.72 million
• Price / Sales: 15.70
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.53 per share
• Price / Book: 1.37

Miscellaneous

• Outstanding Shares: 28,423,000
• Free Float: 23,364,000
• Market Cap: $293.89 million
• Optionable: Optionable
• Beta: 2.48